Gastrointestinal stromal tumour (GIST)—sunitinib malate
On this page
Authority to supply sunitinib malate (Sutent®) for the treatment of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour (GIST), who have a World Health Organization (WHO) performance status of two or less and who have failed imatinib mesylate treatment due to resistance or intolerance, through the Pharmaceutical Benefits Scheme is provided under the Section 85 arrangements of the National Health Act 1953.
Note: sunitinib malate is not PBS subsidised for the treatment of patients with resectable malignant GIST.
Restriction details
View a full transcript of the restriction details.
Item details
Dose
Sunitinib malate is available in a capsule form:
- 12.5 mg capsules in a pack size of 28
- 25 mg capsules in a pack size of 28
- 50 mg capsules in a pack size of 28
Patient eligibility
Patients must meet the relevant restrictions as per the criteria and be eligible to receive pharmaceutical benefits.
Lodgement procedures
Applications for initial approvals must be in writing.
Please send all written applications to:
Medicare Australia
Prior written approval of specialised drugs
Reply Paid 9826
Hobart TAS 7001
(No stamp required if posted in Australia)
For more information call 1800 700 270** (option 3) between 8.00 am and 5.00 pm EST Monday to Friday.
Application form
Initial PBS subsidised treatment for GIST – sunitinib malate PBS authority application supporting information form 4224 [PDF, 200Kb]
. Lodge this form for a patient starting initial PBS subsidised sunitinib malate treatment for GIST, following failure of imatinib mesylate treatment due to resistance or intolerance.
** Call charges apply from mobile and pay phones only
Some documents on this page may require the free Adobe PDF reader.
Last updated: 1 September, 2011